April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Results Of Systemic Immunosuppresion (SI) In High Risk Penetrating Keratoplasty (HRPK)
Author Affiliations & Notes
  • Joanna Major
    Ophthalmology, SPKSO, Warszawa, Poland
  • Jacek P. Szaflik
    Ophthalmology, SPKSO, Warszawa, Poland
  • Mieczyslaw Lao
    Ophthalmology, SPKSO, Warszawa, Poland
  • Jerzy Szaflik
    Ophthalmology, SPKSO, Warszawa, Poland
  • Footnotes
    Commercial Relationships  Joanna Major, None; Jacek P. Szaflik, None; Mieczyslaw Lao, None; Jerzy Szaflik, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 372. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joanna Major, Jacek P. Szaflik, Mieczyslaw Lao, Jerzy Szaflik; Results Of Systemic Immunosuppresion (SI) In High Risk Penetrating Keratoplasty (HRPK). Invest. Ophthalmol. Vis. Sci. 2011;52(14):372.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : HRPK remains challenging due to risk of allograft rejection. Introduction of immunosuppressives (mycophenolate mofetil - MMF, tacrolimus, cyclosporine A - CsA) made it possible to extent corneal graft survival.

Methods: : From January 2009 to March 2010 35 patients had SI administered contemporaneously with keratoplasty. Indications for IS were repeated allotransplatations, coexistence of local or multiorgan immunopathies. Some patients had 2 or more risk factors. SI was introduced after excluding possible contraindications. The double drug therapy (S + MMF) was introduced in most of the cases: steroids (S) i.v. followed by oral tapered doses of prednisone/methylprednisone (P/MP), MMF in initial dose of 1000 mg b.i.d adjusted to reach predose (C0) of MPA concentration of 2- 4 µg/ml. In some cases (3rd or 4th corneal transplantation due to graft failure) tripple therapy: S + MMF + CsA (S. Neoral 3 mg/kg and tapered to reach C0 100ng/ml) was administered. Prophylaxis for 6 months with acyclovir (2 x 800 mg) and Co-trimazole (2 x 480 mg) was introduced. Topical treatment consisted of loteprendol etabonate, quinolone, mydriatics and lubricants. SI was tapered: S to the dose of 5/4 mg of P/MP o.d, CsA and MMF were withdrawn after 6-8 and 12-14 months accordingly.

Results: : No graft rejection was observed during IS. Best corrected visual acuity (BCVA) was from counting fingers (1 patient) to 0.7, average 0.32 examined 5-14 months (average 9.7) after surgery. Over 90% (n= 32) of the patients were IgG (+) for CMV however none of them were IgM (+) prior to therapy. 2 patients developed leucopenia resolving after MMF dose reduction and 2 had moderate increase of serum creatinine concentration controlled by CsA dose reduction. 1 patient died of colon cancer with metastases to liver (she was asymptomatic prior to KP, had negative history of gastric problems, negative benzidine and cancer antigens tests, negative colonoscopy). Neocancerogenesis due to MMF use cannot be excluded but it seems unlikely because MMF is considered less active in cancerogenesis than CsA and treatment of 6 months is to short to induce the process. 2 patients resigned.

Conclusions: : IS is a valuable treatment option increasing graft survival in HRPK.

Keywords: transplantation • drug toxicity/drug effects • corticosteroids 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.